{
  "abstract": "Background and Importance Pharmacogenetic analysis plays a key role in targeted therapy, especially in oncology and haematology. According to the ‘Recommendations for Pharmacogenetic Analysis’ (AIOM-SIF), it is necessary to evaluate if there are mutations in the DPYD and UGT genes in patients eligible for fluoropyrimidine- and irinotecan-based therapies. In the case of heterozygous or homozygous polymorphisms in the DPYD and UGT genes, the oncologist may reduce the dose by 50% to 85%.Aim and Objectives The study compares pharmacogenetic analyses of the DPYD and UGT genes from January 1 to June 20, 2022 and 2023, at an italian hospital.Material and Methods The Hospital started a process for the implementation of pharmacogenetic testing, which involves the Hospital Pharmacy’s collaboration with the Genetics Laboratory and the Oncology Department. Upon receiving the patient, the oncologist requests a pharmacogenetic analysis from the Genetics Laboratory to identify any polymorphisms. The test is performed using real-time PCR, and is processed within 48 hours. The prescriptions are sent electronically to the pharmacist, who evaluates the formalities and appropriateness before proceeding with the treatment.Results From 2020, genotyping tests was performed on 454 patients. In 2022, 78 patients with DPYD: 84.6% wild-type genotype and administration of 100% of the standard dose; 11.5% heterozygous DPYD*6 mutation when the dose was reduced to 85%; 2.6% DPYD*2 and D949V mutations when the dose was reduced to 50%; and 1.3% homozygous mutation. In 2023, out of 48 patients, 77% had a wild-type genotype, 14.5% had a heterozygous DPYD*6 mutation, 2.1% had a heterozygous mutation for the IVS10C>G polymorphism and a 50-75% dose reduction, 2.1% were homozygous for the IVS10C>G polymorphism,the remainder had a heterozygous mutation D949V. In 2022, for the UGT1A gene, out of 58 patients, 46.55% were wild-type, 38% had a heterozygous polymorphism, administering 100% of the dose, and 15.45% had a homozygous mutated genotype with a 70% dose reduction. In 2023, out of 22 patients: 59% were wild-type, 36.4% had heterozygous polymorphism, 4.56% had homozygous mutationConclusion and Relevance Pharmacists play a key role in the application of pharmacogenetic analyses for resource management purposes. Pharmacogenetic analysis is important for pharmacological and clinical perspective,allows for rational resource management improving patient compliance.References and/or Acknowledgements 1. https://www.aiom.itConflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Aou San Giovanni Di Dio E Ruggi D’aragona-Salerno, Farmacia, Salerno, Italy"
      ],
      "name": "M Del Pizzo"
    },
    {
      "affiliations": [
        "Azienda Ospedaliera S.G.Moscati-Avellino, Farmacia, Avellino, Italy"
      ],
      "name": "L Milone"
    },
    {
      "affiliations": [
        "Aorn S.G.Moscati, Laboratorio Genetica Medica, Avellino, Italy"
      ],
      "name": "C Carlo"
    },
    {
      "affiliations": [
        "Aorn S.Giuseppe Moscati, Farmacia, Avellino, Italy"
      ],
      "name": "L Giannelli"
    }
  ],
  "title": "5PSQ-125 The application of pharmacogenetic analysis in a hospital in a Italian region",
  "uid": "03c4c55f-f930-511d-b885-f3922cf0db50"
}